IQVIA Holdings Inc. (NYSE:IQV) Position Trimmed by Teachers Retirement System of The State of Kentucky

Teachers Retirement System of The State of Kentucky trimmed its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 76.3% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 15,878 shares of the medical research company’s stock after selling 51,104 shares during the period. Teachers Retirement System of The State of Kentucky’s holdings in IQVIA were worth $3,674,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Beacon Financial Group lifted its position in IQVIA by 3.4% in the 4th quarter. Beacon Financial Group now owns 4,089 shares of the medical research company’s stock worth $946,000 after buying an additional 133 shares in the last quarter. Raleigh Capital Management Inc. raised its holdings in IQVIA by 4.5% in the 4th quarter. Raleigh Capital Management Inc. now owns 1,157 shares of the medical research company’s stock worth $268,000 after acquiring an additional 50 shares during the period. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main raised its holdings in IQVIA by 339.6% in the 4th quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 2,067,195 shares of the medical research company’s stock worth $478,308,000 after acquiring an additional 1,597,003 shares during the period. L1 Capital International Pty Ltd bought a new position in IQVIA in the 4th quarter worth $5,011,000. Finally, Cadian Capital Management LP bought a new position in IQVIA in the 4th quarter worth $70,108,000. 89.62% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the company. SVB Leerink initiated coverage on IQVIA in a research report on Monday, February 26th. They set an “outperform” rating and a $290.00 price objective on the stock. Leerink Partnrs restated an “outperform” rating on shares of IQVIA in a research note on Monday, February 26th. Evercore ISI dropped their price objective on shares of IQVIA from $275.00 to $250.00 and set an “outperform” rating for the company in a research note on Friday, May 3rd. Truist Financial dropped their price objective on shares of IQVIA from $297.00 to $292.00 and set a “buy” rating for the company in a research note on Friday, May 3rd. Finally, Robert W. Baird dropped their price objective on shares of IQVIA from $254.00 to $245.00 and set a “neutral” rating for the company in a research note on Friday, May 3rd. Three investment analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. According to MarketBeat.com, IQVIA currently has an average rating of “Moderate Buy” and a consensus price target of $258.40.

IQVIA Trading Down 0.2 %

IQV opened at $212.93 on Wednesday. The company has a current ratio of 0.88, a quick ratio of 0.88 and a debt-to-equity ratio of 2.02. The stock has a market capitalization of $38.80 billion, a PE ratio of 29.09, a PEG ratio of 1.94 and a beta of 1.54. IQVIA Holdings Inc. has a 1-year low of $167.42 and a 1-year high of $261.73. The firm has a 50-day moving average price of $226.94 and a two-hundred day moving average price of $230.40.

IQVIA (NYSE:IQV) last posted its quarterly earnings data on Thursday, May 2nd. The medical research company reported $2.30 earnings per share for the quarter, beating the consensus estimate of $2.19 by $0.11. The firm had revenue of $3.74 billion during the quarter, compared to analysts’ expectations of $3.69 billion. IQVIA had a net margin of 9.01% and a return on equity of 29.17%. As a group, equities analysts anticipate that IQVIA Holdings Inc. will post 10.11 earnings per share for the current fiscal year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.